A detailed history of Stifel Financial Corp transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Stifel Financial Corp holds 24,096 shares of FATE stock, worth $39,999. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,096
Previous 41,487 41.92%
Holding current value
$39,999
Previous $136,000 38.24%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.12 - $5.57 $54,259 - $96,867
-17,391 Reduced 41.92%
24,096 $84,000
Q2 2024

Aug 13, 2024

SELL
$3.26 - $7.08 $7,507 - $16,305
-2,303 Reduced 5.26%
41,487 $136,000
Q1 2024

May 13, 2024

SELL
$3.54 - $8.35 $566 - $1,336
-160 Reduced 0.36%
43,790 $321,000
Q4 2023

Feb 12, 2024

SELL
$1.65 - $3.94 $33,295 - $79,505
-20,179 Reduced 31.47%
43,950 $164,000
Q3 2023

Nov 13, 2023

SELL
$2.02 - $5.04 $10,388 - $25,920
-5,143 Reduced 7.42%
64,129 $135,000
Q2 2023

Aug 14, 2023

BUY
$4.76 - $6.59 $80,620 - $111,614
16,937 Added 32.36%
69,272 $329,000
Q1 2023

May 12, 2023

SELL
$4.24 - $11.12 $6,487 - $17,013
-1,530 Reduced 2.84%
52,335 $298,000
Q4 2022

Feb 13, 2023

BUY
$9.86 - $23.83 $110,530 - $267,134
11,210 Added 26.28%
53,865 $543,000
Q3 2022

Nov 14, 2022

SELL
$21.04 - $36.06 $80,393 - $137,785
-3,821 Reduced 8.22%
42,655 $956,000
Q2 2022

Aug 15, 2022

BUY
$17.78 - $42.39 $24,963 - $59,515
1,404 Added 3.12%
46,476 $1.15 Million
Q1 2022

May 13, 2022

BUY
$29.67 - $60.28 $161,108 - $327,320
5,430 Added 13.7%
45,072 $1.75 Million
Q4 2021

Feb 14, 2022

BUY
$47.84 - $64.34 $666,506 - $896,384
13,932 Added 54.19%
39,642 $2.32 Million
Q3 2021

Nov 15, 2021

BUY
$59.27 - $95.73 $819,111 - $1.32 Million
13,820 Added 116.23%
25,710 $1.52 Million
Q2 2021

Aug 13, 2021

BUY
$67.25 - $92.52 $214,796 - $295,508
3,194 Added 36.73%
11,890 $1.03 Million
Q1 2021

May 14, 2021

BUY
$72.16 - $117.4 $76,273 - $124,091
1,057 Added 13.84%
8,696 $717,000
Q4 2020

Feb 12, 2021

SELL
$38.09 - $100.95 $12,531 - $33,212
-329 Reduced 4.13%
7,639 $695,000
Q3 2020

Nov 16, 2020

BUY
$30.41 - $40.5 $12,711 - $16,929
418 Added 5.54%
7,968 $318,000
Q2 2020

Aug 14, 2020

BUY
$20.21 - $35.23 $152,585 - $265,986
7,550 New
7,550 $259,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.